The Good, The Bad, and The Incretins: Unlocking the Potential of Incretins
GLP-1 and similar medications have revolutionised weight management and emerging research continues to discover a plethora of health benefits. There is a vast potential to improve patient outcomes in cardiovascular health, immune function, cognition and brain function. The emerging research demonstrates new opportunities for natural healthcare practitioners to expand their clinical insights and scope of practice.
These medications are not without their challenges, and for many come at a cost. Effects and compliance issues such as high attrition rates, variable patient response, concerning loss of lean muscle, and significant gastrointestinal distress, further underscore the need for a whole-person practitioner approach.
We are at the tip of the iceberg with this revolution of incretin and other endocrine mimetics. Innovations into incretins and peptides derived from gut, muscle, bone and brain are showing synergistic effects with the ‘traditional’ GLP-1 receptor agonists, highlighting the need for healthcare practitioners to be aware of the growing landscape of therapies and potential mechanisms.
Join us to discover:
How GLP-1 therapies extend beyond weight management to support cardiovascular, immune, and cognitive health.
Strategies to address common challenges such as lean muscle loss, gastrointestinal side effects, and patient compliance.
Why a whole-person approach is essential for integrating incretin therapies into clinical practice.
Insights into emerging peptide innovations and how they can expand your therapeutic toolkit.
Register for this free one-hour seminar to explore how cutting-edge incretin therapies are reshaping clinical practice and be among the first to discover the broader themes and innovations that will define the Integria Practitioner Symposium 2026.
Read more
